Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | TNNI3 | P19429 | 1/20 | 1.00 |
| ▸ | TNNT2 | P45379 | 1/20 | 1.00 |
| ▸ | TNNC1 | P63316 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.97 |
| ▸ | CTSB | P07858 | 5/20 | 0.75 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.65 |
| ▸ | APAF1 | O14727 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28512817 | 0.88 | MAPT (1.00) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL3627022 | 0.88 | MAPT (0.79) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL6267493 | 0.87 | MAPT (0.77) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL2628834 | 0.84 | MAPT (0.72) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL28524484 | 0.79 | MAPT (0.65) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL29741481 | 0.79 | MAPT (0.65) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL3603749 | 0.79 | CTSB (1.00) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL3598358 | 0.78 | CTSB (0.97) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL6263506 | 0.78 | MAPT (1.00) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 | |
| SCHEMBL5449804 | 0.77 | ALDH1A1 (0.67) | MAPTSMN1; SMN2TNNI3TNNT2TNNC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | claimed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007092391-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | MAPT 3702/4885SMN1; SMN2 3219/4885TNNI3 3521/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | MAPT 3809/4885SMN1; SMN2 3162/4885TNNI3 3434/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | MAPT 3702/4885SMN1; SMN2 3219/4885TNNI3 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.